Jaguar Health, Inc.
crofelemer
rare intestinal failure diseases
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on crofelemer for rare intestinal failure diseases is in focus around Date TBD.
Primary source
· SEC 8-K
verified 14h ago
“the Company for our crofelemer-based prescription drug candidate for rare intestinal failure diseases.”